News
ONTX
--
0.00%
--
Top Penny Stocks To Buy Under $1? 4 Cheap Stocks For Your List
Jan 18, 2021 (Penny Stocks via COMTEX) -- Should You Buy Cheap Stocks Under $1 Right Now? When it comes to making money in the stock market, there are plenty...
Penny Stocks · 01/18 16:34
8-K: Onconova Therapeutics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/16 03:09
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, President & CEO, will present a Company overview ...
GlobeNewswire · 01/14 13:00
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, P...
GlobeNewswire · 01/14 13:00
Onconova Therapeutics announces $8.7M registered direct offering
Onconova Therapeutics ([[ONTX]] +0.7%) to issue ~19.6M shares at $0.445 share in a registered direct offering, for gross proceeds of $8.7M.Offering is expected to close on January 11. Net proceeds will
Seekingalpha · 01/07 14:49
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain institutional a...
GlobeNewswire · 01/07 14:40
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive...
GlobeNewswire · 01/07 14:40
Thinking about buying stock in Sundial Growers, BioNano Genomics, Zomedica, Jaguar Health, or Onconova Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, BNGO, ZOM, JAGX, and ONTX.
PR Newswire - PRF · 01/06 15:55
Onconova cleared to start Phase 1 trial for cancer therapy
Onconova Therapeutics (ONTX) has received the FDA signoff for its Investigational New Drug application for ON 123300, a first-in-class multi-kinase inhibitor targeting tumor-driving kinases including CDK4/6 and ARK5.With the FDA go-ahead, the
Seekingalpha · 12/24/2020 17:03
WATT, MVIS, SOL and ONTX among midday movers
Gainers: Jaguar Health (JAGX) +191%.Ocugen (OCGN) +177%.Acasti Pharma (ACST) +88%.Scopus BioPharma (SCPS) +50%.Foresight Autonomous Holdings (FRSX) +35%.Onconova Therapeutics (ONTX) +32%.Evogene (EVGN) +31%.Energous Corporation (WATT) +29%.VivoPower International (VVPR) +26%.Phoenix New Media
Seekingalpha · 12/23/2020 17:36
Thinking about buying stock in Onconova Therapeutics, Jaguar Health, Acasti Pharma, Zomedica, or Riot Blockchain?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, JAGX, ACST, ZOM, and RIOT.
PR Newswire - PRF · 12/23/2020 15:55
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced receipt of U.S. Food and Drug Administration (FDA) permission for a Phase 1 study to proceed under...
GlobeNewswire · 12/21/2020 13:00
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
GlobeNewswire · 12/21/2020 13:00
Advanced Testing Options Help Alter the Fight Against Cancer
, /PRNewswire/ -- The global biopharmaceutical market is driven by many complex factors. These include an increase in the elderly population, surges in prevalence of chronic diseases such as cancer and diabetes, and an increase in adoption of biopharmaceu...
PR Newswire - PRF · 12/09/2020 14:00
Thinking about buying stock in Sundial Growers, Zomedica, Advanced Micro Devices, Jaguar Health, or Onconova Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, AMD, JAGX, and ONTX.
PR Newswire - PRF · 12/02/2020 15:50
Thinking about buying stock in Sundial Growers, Zomedica, Advanced Micro Devices, Jaguar Health, or Onconova Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, AMD, JAGX, and ONTX.
PR Newswire - PRF · 12/02/2020 15:50
BB, QS, ONTX and TTNP among middy movers
Gainers: Auris Medical (EARS) +360%.BlackBerry (BB) +53%.Corporacion America Airports (CAAP) +41%.Onconova Therapeutics (ONTX) +36%.Jaguar Health (JAGX) +29%.Xunlei (XNET) +29%.Codiak BioSciences (CDAK) +27%.Arlo Technologies (ARLO) +27%.F-star Therapeutics (FSTX) +21%.ReWalk Robotics (RWLK) +19%.Losers: Aaron's Holdings (AAN) -70%.SYNNEX
Seekingalpha · 12/01/2020 17:52
Thinking about buying stock in Jaguar Health, Zomedica, Sundial Growers, Onconova Therapeutics, or Transocean?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, ZOM, SNDL, ONTX, and RIG.
PR Newswire - PRF · 12/01/2020 15:39
Return On Capital Employed Overview: Onconova Therapeutics
During Q3, Onconova Therapeutics (NASDAQ: ONTX) brought in sales totaling $66.00 thousand. However, earnings decreased 14.51%, resulting in a loss of $6.27 million. Onconova Therapeutics collected $56.00 thousand in revenue during Q2, but reported earnings showed a $7.34 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Onconova Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Onconova Therapeutics posted an ROCE of -0.51%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on ONTXReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Onconova Therapeutics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q3 Earnings Insight Onconova Therapeutics reported Q3 earnings per share at $-0.03/share, which did not meet analyst predictions of $-0.03/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 12/01/2020 15:27
Return On Capital Employed Overview: Onconova Therapeutics
During Q3, Onconova Therapeutics (NASDAQ: ONTX) brought in sales totaling $66.00 thousand. However, earnings decreased 14.51%, resulting in a loss of $6.27 million. Onconova Therapeutics collected $56.00 thousand in revenue during Q2, but reported earnings...
Benzinga · 12/01/2020 15:27
Webull provides a variety of real-time ONTX stock news. You can receive the latest news about Onconova through multiple platforms. This information may help you make smarter investment decisions.
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.